Cytodel

CytoDel is pioneering a novel drug delivery platform using engineered, atoxic recombinant botulinum neurotoxins (rBoTs) to transport therapeutic payloads directly into the neuronal cytoplasm, a previously inaccessible target space. Its lead programs focus on biodefense as a botulism antidote and on developing 'biobetter' neurotoxins for neurological conditions and chronic pain. With an exclusive license from NYU Grossman School of Medicine and completed Series A financing, the company is advancing its preclinical pipeline to address high unmet medical needs in neurology and national security.

Proprietary platform for engineering recombinant botulinum toxin (rBoT) derivatives. The technology inactivates the native toxin's protease and repurposes its neuron-targeting heavy chain to deliver therapeutic antibody payloads (Antibody Fusion Proteins) into the neuronal cytoplasm. Also enables creation of 'biobetter' BoNTs with customized safety profiles.

In intraneuronal delivery, CytoDel appears to be a pioneer with a unique platform, facing no direct competitors. In the botulinum toxin market, it would compete against established giants like AbbVie (Botox) and others, but its recombinant 'biobetter' approach offers potential differentiation through engineering for improved safety and efficacy.